In the hs-cTnI elevation group, patients had more comorbid AF and CAD, more previous antithrombotic therapy, higher hs-cTnI dynamic change rate, higher INR, more insula involvement, a lower level of LDL-C, and higher mortality than the comparison group (all p<0.05; see online supplemental table 4). The gene discussed is TNNI3; the disease is coronary artery disorder.